Navigation Links
New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
Date:10/25/2008

rienced a reduction in disease signs and symptoms at one year compared with patients treated with placebo plus methotrexate. At 52 weeks, 56 percent, 36 percent and 20 percent of RA patients treated with ACTEMRA 8 mg/kg plus methotrexate achieved ACR20, ACR50 and ACR70(2), respectively, and 47 percent, 29 percent and 16 percent of patients in the ACTEMRA 4 mg/kg arm achieved these ACR scores, respectively. In contrast, 25 percent, 10 percent and 4 percent of patients in the control group achieved ACR20, ACR50 and ACR70, respectively. Disease remission (DAS28 <2.6)(3) was demonstrated in 47 percent and 30 percent of patients treated with ACTEMRA 8 mg/kg and 4 mg/kg, respectively, at week 52 compared with 8 percent of patients treated with placebo plus methotrexate.

"We've seen in previous studies that patients treated with ACTEMRA experienced an improvement in the signs and symptoms of RA and achieved remission according to the DAS28 criteria more often than with DMARDs," said Kenneth Bahrt, M.D., Global Medical Director, Autoimmunity, Roche. "The LITHE study not only confirmed these data, but for the first time demonstrated that ACTEMRA also significantly inhibited the progression of structural joint damage in patients with RA."

At one year, the study also showed that there was improved physical function following treatment with ACTEMRA, as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI).(4)

About the LITHE Study

LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage), a three-arm, randomized, double-blind, placebo-controlled study, was designed to evaluate the efficacy and safety of ACTEMRA (8 mg/kg or 4 mg/kg) plus methotrexate compared with placebo plus methotrexate in RA patients for the prevention of structural joint damage, improvement in physical function and disease signs and symptoms. Patients received either ACTEMRA

intravenously every four weeks plus methotrexate weekly or place
'/>"/>

SOURCE Hoffmann-La Roche Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
3. Life Recovery Systems Receives NIH Grant to Study Expanded Use of Its ThermoSuit System
4. Mindset Media Study Reveals Which Independent Voters Favor Obama Vs. McCain
5. Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkins Lymphoma
6. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
7. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
8. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
9. Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques
10. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
11. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 Pfenex Inc. (NYSE MKT: PFNX) today announced ... of 8,333,333 shares of its common  stock at a price ... common stock was offered by Pfenex. In addition, Pfenex has ... 1,250,000 additional shares of common stock at the initial public ... the NYSE MKT under the symbol "PFNX." ...
(Date:7/29/2014)... , July 29, 2014  Landauer, Inc. (NYSE: ... and environmental radiation measurement and monitoring, outsourced medical physics ... financial results for the fiscal third quarter 2014 after ... The Company will host a conference call ... a.m. Central Time (10 a.m. Eastern Time). Investors may ...
(Date:7/29/2014)... 29, 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... targeting specific pathogens that cause serious infections and diseases, ... activity in the Company,s stock, the NYSE MKT (the ... usual practice. The Company stated that its policy is ... About Synthetic Biologics, Inc. Synthetic Biologics, Inc. ...
Breaking Medicine Technology:Pfenex Announces Closing of Initial Public Offering 2Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2
... , MINNETONKA, Minn., Dec. 1 ... company specializing in clinical study management systems, today ... technology solution, has been certified by the Clinical ... the Operational Data Model (ODM) standard. This ...
... , CAMBRIDGE, Mass. and TOKYO, Dec. 1 Galenea ... further extension of their research and development collaboration through ... to seven years and brings the total committed funding ... working together since January 2005 with the goal of ...
Cached Medicine Technology:MedNet Solutions' ENLIGHTEN Receives CDISC ODM Certification 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 3
(Date:7/29/2014)... Using quality improvement measures in eight of the 10 ... Group, researchers have found a way to reduce kidney ... , Currently, 7-15 percent of these patients who undergo ... kidney injury, which can result in death or rapid ... dialysis, says a study published in the July issue ...
(Date:7/29/2014)... Historically, Memorial Day kicks off a three ... throughout that time by picnics, barbecues and beach outings. ... the start of a period that will witness a ... 2012 nearly 1.000 people were killed in crashes involving ... Labor Day. , The summer's warmer weather, longer days ...
(Date:7/29/2014)... During his 37 years in dental practice, ... has had a steady stream of college students shadow him ... now gone on to dental school and some are now ... program helps college students find success. , For students interested ... the chance to see a realistic view of what goes ...
(Date:7/29/2014)... 29, 2014 A team of scientists, ... Ethell, PhD, has developed a blood test for Alzheimer’s ... the development of Alzheimer’s disease interventions, according to an ... a puzzle, and this study represents one of several ... the past couple of years,” Ethell said. , The ...
(Date:7/29/2014)... Just months after the recent announcement ... states, the exciting FX family does it again! Michael ... farmboy from Arkansas, is shocking the world with his ... to the masses. This time with their first ... Jamaica. This new office is scheduled to handle ...
Breaking Medicine News(10 mins):Health News:Reducing kidney injury using a quality improvement method 2Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2Health News:Arthur Bruce Dental Helps College Students 2Health News:Professor Develops Blood Test for Alzheimer’s Disease Risk 2Health News:Atlanta Special FX Rapidly Expanding Just Opens First International Corporate Office in Jamaica 2
... Decreased muscle strength is associated with difficulty in ... kneeling (SCK) in older adults, according to an ... Physical Therapy (PTJ), the scientific journal ... researchers found that adults with SCK difficulty had ...
... They differ from each other in many ways, and they ... HIV to resist a host of weapons fired at ... emerging. One potential weapon is a small-molecule ... by attacking them through some feature common to an entire ...
... ... a Soho Seminar event that will help you transform the way employees engage inside and ... ... at the Soho Seminars event “Aligning the Corporate and Personal Brand,” hosted by Loyola ...
... effect on heart from androgen deprivation, official says ... with prostate cancer and the physicians who treat ... (ADT) commonly used against the malignancy might increase ... , "There is a substantial amount of data ...
... , PHILADELPHIA , ... GlaxoSmithKline plc will announce its full year financial results for the ... the announcement will be released to the London Stock Exchange at ... www.gsk.com . , Following the announcement, Andrew Witty , ...
... , , Rare, but serious, liver disorder ... 1 The U.S. Food and Drug Administration today announced ... has been reported in some HIV patients taking Videx/Videx EC ... is an antiretroviral medicine first approved by the FDA in ...
Cached Medicine News:Health News:Decreased muscle strength predicts functional impairments in older adults 2Health News:Decreased muscle strength predicts functional impairments in older adults 3Health News:Researchers find 'broad spectrum' antiviral that fights multitude of viruses 2Health News:Researchers find 'broad spectrum' antiviral that fights multitude of viruses 3Health News:7Summits to Present at Soho Seminars 'Alignment of Personal and Corporate Brands' 2Health News:Experts Issue Warning on Prostate Hormone Therapy 2Health News:Experts Issue Warning on Prostate Hormone Therapy 3Health News:GSK 2009 Financial Results Announcement and Teleconference Details 2Health News:FDA Announces Safety Risk Associated with HIV Drug 2
0.5mm 1X2 Teeth with 6mm Tying Platform; in Stainless Steel 125...
... necessary addition to any ... Reichert Trial Frame provides ... smooth controls for quick, ... design, high-quality materials, and ...
... CTS utilizes a small-cone design and ... a complete, shadow-free representation of the ... system that includes the topographer, PC, ... software enables quick and easy access ...
... AL500 incorporates all of the features you ... well as a color display, auto add-lock, ... design fits easily into your existing workspace, ... glare-free viewing at any angle.,Quick and accurate, ...
Medicine Products: